ArticleClinical and translational radiation oncology2026
Daily adaptive radiotherapy in postoperative hypofractionated salvage radiothERapy for prostate cancer patients (DART-PHASER): Early clinical and dosimetric results.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05884632 (Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate dose-volume histogram metrics and preliminary toxicity of prostate cancer (PC) patients affected by postoperative locoregional relapse treated with moderately hypofractionated salvage radiotherapy (sRT) using AI-assisted daily adaptive RT. Methods: This is a prospective observational study (4181CESC, NCT05884632) on adaptive hypofractionated sRT in PC. Eligible patients (up to 80 years old, post-prostatectomy, PSMA PET-CT confirmed M0) received 20 daily fractions up to 59 Gy for macroscopic relapse and 55 Gy for biochemical-only relapse. When indicated, pelvis was included with a dose of 45 Gy. The treatment was administered using Ethos™ system which generates two plans: scheduled and adapted. The scheduled plan includes a dose recalculation on daily synthetic CT (generated from daily CBCT). The adapted plan consists on a reoptimization based on the daily anatomy. The user then select the preferred one for treatment. This is an interim analysis reporting on DVH metrics (scheduled versus adapted plan) and toxicity outcome. Results: The results of the first 840 treatment fractions in 42 patients are reported. Sixteen (37.2%) had biochemical relapse only, while 27 (62.8%) had macroscopic relapse. We reported a significant improvement between scheduled and adapted plan for rectum V52.8Gy (16.9% versus 12.8%); Conclusion: Preliminary data seems to show minimal acute toxicity. A longer follow up is needed to confirm these data and evaluate late toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.